Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMFU0JY)

Drug Name
TH-302 Drug Info
Synonyms
TH-302; evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; TH-302; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174
Cross-matching ID
PubChem CID
11984561
ChEBI ID
CHEMBL260046
CAS Number
CAS 918633-87-1
TTD Drug ID
D0H1EA

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Allograft rejection 2.41 0.00e+0 32/38 (84.21%) HLA-B;HLA-DQA1;CD40;...
Type I diabetes mellitus 2.38 0.00e+0 38/43 (88.37%) HLA-B;HLA-DQA1;HLA-DRA;...
Autoimmune thyroid disease 2.32 0.00e+0 46/53 (86.79%) HLA-B;HLA-DQA1;CD40;...
Parkinson disease 2.29 0.00e+0 176/249 (70.68%) UCHL1;DAXX;TXN;...
Antigen processing and presentation 2.28 0.00e+0 60/78 (76.92%) HLA-B;HLA-DQA1;HLA-DRA;...
Huntington disease 2.27 0.00e+0 233/306 (76.14%) IFT57;PLCB3;TUBB2A;...
Proteasome 2.24 0.00e+0 44/46 (95.65%) PSMB8;PSMB4;PSMC2;...
Oxidative phosphorylation 2.23 0.00e+0 93/133 (69.92%) COX6A1;ATP5MC3;COX4I1;...
Amyotrophic lateral sclerosis 2.18 0.00e+0 267/364 (73.35%) NEFH;DAXX;NEFM;...
Asthma 2.17 0.00e+0 25/31 (80.65%) HLA-DQA1;CD40;HLA-DRA;...
Graft-versus-host disease 2.16 0.00e+0 32/42 (76.19%) HLA-B;HLA-DQA1;HLA-DRA;...
Pathways of neurodegeneration 1.94 4.23e-3 354/475 (74.53%) UCHL1;NEFH;IFT57;...
Prion disease 1.90 4.68e-3 209/273 (76.56%) NOTCH1;TUBB2A;COX6A1;...
Inflammatory bowel disease 1.85 5.80e-3 58/65 (89.23%) TLR4;MAF;HLA-DQA1;...
Ribosome 1.84 6.76e-3 113/158 (71.52%) RPS5;RPL35A;RPS27L;...
Phagosome 1.74 2.28e-2 118/152 (77.63%) TLR4;HLA-B;HLA-DQA1;...
Alzheimer disease 1.73 2.45e-2 279/369 (75.61%) PLCB3;TUBB2A;COX6A1;...
Basal cell carcinoma 1.71 3.16e-2 41/63 (65.08%) BMP4;GADD45B;CDKN1A;...
Thermogenesis 1.71 3.15e-2 173/232 (74.57%) KDM3A;ACSL5;COX6A1;...
Th1 and Th2 cell differentiation 1.69 3.75e-2 80/92 (86.96%) MAF;NOTCH1;HLA-DQA1;...
Diabetic cardiomyopathy 1.66 4.44e-2 162/203 (79.8%) PLCB3;COX6A1;TGFBR2;...
Viral myocarditis 1.65 4.47e-2 53/60 (88.33%) HLA-B;HLA-DQA1;CD40;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H